Funobactam

Funobactam
Clinical data
Other names	XNW-4107
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name [(2S,5R)-2-[5-[(5S)-2-amino-4,5-dihydro-1H-imidazol-3-ium-5-yl]-1,3,4-oxadiazol-2-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] sulfate;
CAS Number	2365454-12-0;
PubChem CID	164888918;
IUPHAR/BPS	13114;
ChemSpider	128921712;
UNII	6WG7OYL77A;
Chemical and physical data
Formula	C13H17N7O6S
Molar mass	399.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC12C[C@H](N3C[C@@H]2N(C3=O)OS(=O)(=O)[O-])C4=NN=C(O4)[C@@H]5C[NH+]=C(N5)N;
	InChI InChI=1S/C13H17N7O6S/c14-11-15-4-6(16-11)9-17-18-10(25-9)7-3-13(1-2-13)8-5-19(7)12(21)20(8)26-27(22,23)24/h6-8H,1-5H2,(H3,14,15,16)(H,22,23,24)/t6-,7-,8-/m0/s1; Key:GRRBXZJDEZJMHA-FXQIFTODSA-N;

Funobactam is an investigational new drug that is being evaluated for the treatment of hospital-acquired bacterial pneumonia.^[1] It is a β-lactamase inhibitor.^[2]

References

^ Clinical trial number NCT05204563 for "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (REITAB-2)" at ClinicalTrials.gov
^ Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, et al. (June 2024). "Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations". International Journal of Molecular Sciences. 25 (13): 6814. doi:10.3390/ijms25136814. PMC 11241693. PMID 38999924.